Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Receivables (2023 - 2025)

Syndax Pharmaceuticals (SNDX) has 3 years of Receivables data on record, last reported at $41.7 million in Q4 2025.

  • For Q4 2025, Receivables rose 271.06% year-over-year to $41.7 million; the TTM value through Dec 2025 reached $41.7 million, up 271.06%, while the annual FY2025 figure was $41.7 million, 271.06% up from the prior year.
  • Receivables reached $41.7 million in Q4 2025 per SNDX's latest filing, up from $29.1 million in the prior quarter.
  • Across five years, Receivables topped out at $41.7 million in Q4 2025 and bottomed at $1.2 million in Q4 2023.
  • Average Receivables over 3 years is $20.7 million, with a median of $20.4 million recorded in 2025.
  • Peak YoY movement for Receivables: soared 815.81% in 2024, then soared 271.06% in 2025.
  • A 3-year view of Receivables shows it stood at $1.2 million in 2023, then skyrocketed by 815.81% to $11.2 million in 2024, then skyrocketed by 271.06% to $41.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $41.7 million in Q4 2025, $29.1 million in Q3 2025, and $21.5 million in Q2 2025.